Sarepta Shares Bounce As Pfizer’s DMD Gene Therapy Sparks Safety Concerns

Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.

Baseball
Sarepta bounces on Pfizer data but will it win the game? • Source: Shutterstock

Pfizer Inc. has allowed a peek into its Phase Ib clinical data on PF-06939926, its investigational gene therapy for Duchenne muscular dystrophy (DMD), and while it does show some signs of efficacy, safety is a concern.

The primary endpoint of the ongoing Phase Ib study is to assess the safety and tolerability of the gene therapy,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies